ResMed (RMD) is higher today as positioning builds into the company’s next quarterly earnings release, which the company scheduled for April 30, 2026 after the NYSE close. With the date now on the calendar, traders are leaning into a near-term catalyst as the market reassesses the pace of revenue growth and the durability of margin expansion trends highlighted in recent quarters. (stocktitan.net)

Recent sell-side changes have stayed constructive. A notable example is KeyBanc’s recent price-target increase, framed around a view that the company’s prior results showed sustained margin inflection and generally positive operating momentum. While the target change itself was small, the rationale reinforces a broader bullish setup into earnings focused on profitability and mix rather than purely top-line acceleration. (tipranks.com)

RMD has meaningful short interest relative to its float, which can increase sensitivity to positive incremental news and catalyst-driven repositioning. In a setup like this—earnings approaching and sentiment improving—day-to-day price moves can be amplified when short covering or options hedging overlaps with fundamental buyers. (marketbeat.com)

The key near-term read-through will be management’s commentary on demand trends across sleep and respiratory devices, the trajectory of gross margin, and any updated outlook delivered alongside the April 30, 2026 results. Investors will also watch for signals about product cycle momentum and whether recent profitability improvements are holding as volume and competition evolve. (stocktitan.net)